LAMP1 and infection: Ninety‐five percent of individuals appear to seroconvert following the Sinopharm/BBIBP‐CorV vaccine, and the vaccine appears to induce similar levels of ACE2 receptor blocking antibodies and RBD binding antibodies to delta variant as seen following natural infection; 27.7% of individuals had ex vivo IFNγ ELISpot responses to the vaccine, while CD107a expression was predominantly seen from the CD4+ subset of T cells.